DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 21, 2004; DOI: 10.1124/dmd.104.001107


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.001107v1
32/12/1341    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cho, J.-Y.
Right arrow Articles by Jang, I.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, J.-Y.
Right arrow Articles by Jang, I.-J.


Received for publication June 22, 2004.
Revised September 14, 2004.
Accepted for publication September 15, 2004.

Haplotype structure and allele frequencies of CYP2B6 in a Korean population

Joo-Youn Cho 1, Hyeong-Seok Lim 1, Jae-Yong Chung 1, Kyung-Sang Yu 1, Jung-Ryul Kim 1, Sang-Goo Shin 1, In-Jin Jang 1*

1 Department of Pharmacology, College of Medicine, Seoul National University

* Address correspondence to: E-mail: ijjang{at}snu.ac.kr

Abstract

Cytochrome P450 2B6 (CYP2B6) metabolizes a number of therapeutic drugs and its metabolic activity varies markedly in human liver. Although genetic polymorphisms of CYP2B6 have been reported in noncoding and coding regions, little information is available regarding single nucleotide polymorphisms (SNPs) and their haplotypes in noncoding regions in Asians. Fourteen previously reported SNPs were determined by PCR-RFLP or SNaPshot analysis in a Korean population and their haplotypes were inferred from genotype data using an expectation-maximization algorithm. The most common haplotypes were haplotype I, the reference sequence (frequency 0.35), haplotype II (0.19), haplotype III (0.19), and haplotype V (0.12), which together accounted for 85% of all haplotypes. The frequency of haplotype III, which contains -2320C, -1778G, -1186G, -750C, and 15582T, was found to be 2.4-fold higher than that of the *1J allele in Caucasians, and the frequency of haplotype V, which contains -8207C, -1456C, -750C, 516T, and 785G, was 55% of that of the *6B allele in Caucasians. Moreover, haplotype V, the *6B allele appeared to be completely linked to -8207 within a putative nuclear receptor binding motif, suggesting that lower expressions of the *6B allele may be associated with the presence of noncoding SNPs such as -8207G>C linked to non-synonymous SNPs. In conclusion, we found 11 previously described polymorphisms and identified four major haplotypes of CYP2B6 in Koreans. The frequencies of the *1J or *6B alleles, which may reduce CYP2B6 enzyme expression, were found to be significantly different between Koreans and Caucasians.


Key words: CYP2B, genetic polymorphism, genotype


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Oezguen, S. Kumar, A. Hindupur, W. Braun, B. K. Muralidhara, and J. R. Halpert
Identification and Analysis of Conserved Sequence Motifs in Cytochrome P450 Family 2: FUNCTIONAL AND STRUCTURAL ROLE OF A MOTIF 187RFDYKD192 IN CYP2B ENZYMES
J. Biol. Chem., August 1, 2008; 283(31): 21808 - 21816.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
E. D. Kharasch, D. Mitchell, and R. Coles
Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity
J. Clin. Pharmacol., April 1, 2008; 48(4): 464 - 474.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.